Peptide Drug CDMO Keyword Candidate Study

Comparative structure study

The largest recorded reporting jurisdiction, Zhejiang, contains 15 records (25.0% of this 60-record cohort). The remaining cohort contains 45 records. The comparison concerns archive composition.

The recorded industry label Biomedicine accounts for 95.0% here (57/60), compared with 8.9% in the parent set (1,721/19,297), an absolute gap of 86.1 percentage points.

24/60 companies link to pages with existing source-supported excerpts (40.0% of the cohort). The other 36 records remain usable for archive composition, but do not support new operating case studies.

An ID-deduplicated archive snapshot, not the whole market, current recognition or operating results.

The parent set, All public archive records, contains 19,297 records. This cohort contributes 60 (0.3%); 19,237 records remain after excluding it.

Ratio of label participation, not market share; multi-label counts overlap.

Excluding this cohort, the recorded industry label Biomedicine covers 1,664/19,237 remaining records (8.6%), an absolute gap of 86.4 percentage points from this cohort.

The full reporting jurisdiction distribution has 18 labels; the top 3 contain 30/60 records (50.0%).Other known labels contain 30 records.

For 60 records with known labels, the effective category count is 8.3, versus 18 actual labels. Definitions and scope are in the methodology.

The table shows ten labels; 8 others are included in the calculations above.

Record counts do not rank supply capability or economic size.

The largest intersection, Zhejiang × Biomedicine, contains 15 records, or 100.0% of the 15 records carrying the Zhejiang label.

A cell contains company IDs carrying both labels. It does not establish procurement, supply or investment relationships between firms. Multi-label cells may overlap.

This page displays 8 of the full cross-tab’s 20 non-empty cells; the other 12 remain in the analysis.

Non-empty fields are not necessarily accurate or supported by originals.

Counts concern existing reviewed bilingual excerpts, not re-certification of originals or entire reports.

A rule hit prioritises review; it does not establish that the entire field is wrong. One record can trigger several rules.

An ID may match several fields, so counts may exceed the cohort total. Matches establish search relevance only.

Among the translated non-broad query terms, “active pharmaceutical ingredients” has the most matches: 50/60. Name, product and sub-industry fields match 0, 49 and 1 records respectively; the largest field is product field. Fields can overlap, and a term remains a search link rather than verified business activity.

Selected broad terms and specific segment terms, not the full query. Terms and fields can overlap and must not be summed. Counts show lexical sensitivity; no records are removed without primary evidence.

9 of this cohort’s 60 records link through existing company-ID mappings to 2026 lists from all jurisdictions (15.0%). This intersection measures list linkage, not successful recognition or company growth.

List rows and company IDs are separate counts, not new firms or final recognition.

Drug-production leads need validation and change records

The Chemical drugs and formulations label covers 40 records (66.7% of this cohort). This archive clue raises a verification question about Defined pharmaceutical-production or testing services with quality documents; it does not establish that these companies already deliver it.

Shared records with Chemical Pharma Preparation Keyword Candidate Study: 55; records in this cohort but outside that set: 5. The intersection/union ratio is 26.8%, a measure of label overlap rather than business collaboration. Read comparison

Shared records with Chemical drugs and formulations / Biomedicine and medical devices / Complete systems and use-case applications Sub-industry and Supply-chain Study: 40; records in this cohort but outside that set: 20. The intersection/union ratio is 24.5%, a measure of label overlap rather than business collaboration. Read comparison

Stable-ID samples, not rankings; metrics use the full cohort.